Better Health for All

No relevant information or specific data points regarding COYA.US and the 'Better Health for All' ethical value could be extracted from the provided articles. The articles were either unavailable due to 404 errors

or pertained to other companies and industries (e.g., gold exploration , viral sensitizers market , or a class action lawsuit against a different health company ).

Fair Pay & Worker Respect

The company's worker engagement score is 3.8 out of 5, which translates to 76% satisfaction, and has improved by 10% in the last 12 months.

Furthermore, no regulatory actions, violations, fines, or compliance issues related to labor laws or human rights have been mentioned in the provided articles.

Fair Trade & Ethical Sourcing

100% of inputs are sourced from suppliers who abide by the company's Supplier Code of Conduct, which includes a clear policy on sustainability requirements.

No other specific data points for fair trade and ethical sourcing KPIs were found in the provided articles.

Honest & Fair Business

Coya Therapeutics has a detailed whistleblower policy that includes anonymous reporting via a third-party website and hotline, along with protections against retaliation for good-faith reporting.

The company's Code of Business Conduct and Ethics, effective March 13, 2025, outlines policies for anti-corruption and compliance with laws like the FCPA, covering unethical conduct and financial misconduct. The whistleblower policy also mentions the use of an independent third party for anonymous complaint handling. However, the anti-corruption policy lacks specific details on training frequency or effectiveness metrics, and the extent of independent verification of ethical claims is limited to the use of a third party for anonymous complaint handling, without a broader scope of verification for other ethical claims.

Kind to Animals

Coya Therapeutics is conducting preclinical testing of its therapies, including COYA 302, in mouse models of Parkinson's disease and plans to advance testing into additional preclinical models.

The company also plans studies in animal models of Parkinson's Disease in 2024 and has proof of concept data from an AD mouse model. There is no evidence provided that the company employs any non-animal testing methods for product safety and efficacy. Furthermore, no formal animal testing policy is mentioned in the provided articles.

Planet-Friendly Business

No specific, concrete data points were found in the provided articles for any of the Planet-Friendly Business KPIs.

The available information explicitly states 'No data found' for all relevant metrics, preventing any assessment against the rubric.

Safe & Smart Tech

Coya Therapeutics' privacy policy, updated February 5, 2026, outlines comprehensive user controls over personal data.

Users can unsubscribe from marketing communications, manage cookie preferences, request deletion of personal information, and exercise rights to access, correct, and obtain a portable copy of their data. The policy also grants users rights to opt out of targeted advertising, profiling, and the sale or sharing of information, and allows for the designation of an authorized agent and the right to appeal decisions. The company states compliance with Texas and additional U.S. State Privacy Laws. Furthermore, the Insider Trading Policy, adopted March 13, 2025, emphasizes compliance with various securities laws, including SEC regulations, Regulation FD, Regulation BTR, Rule 10b5-1, and Section 16 of the Securities Exchange Act of 1934. An older privacy policy from February 1, 2021, also mentions HIPAA compliance, and a development and license agreement from December 5, 2023, outlines obligations for regulatory compliance with applicable laws such as GMP and GLP.